High expression of CXCR3 in tumor cells (3+) was associated with markedly reduced PFS both in the discovery set (11 vs 16 months, P=0.045) and in the validation set (11 vs 22 months, P=0.001; Figures 4a and Table 2). This evidence concerns the gene CXCR3 and neoplasm.